# Evaluate the Efficacy and Safety of DWJ1506 and DWJ1507

> **NCT04772443** · PHASE3 · UNKNOWN · sponsor: **Daewoong Pharmaceutical Co. LTD.** · enrollment: 280 (estimated)

## Conditions studied

- Dyslipidemias

## Interventions

- **DRUG:** DWJ1506
- **DRUG:** DWJ1507
- **DRUG:** DWC202011
- **DRUG:** DWJ1177

## Key facts

- **NCT ID:** NCT04772443
- **Lead sponsor:** Daewoong Pharmaceutical Co. LTD.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2021-02
- **Primary completion:** 2022-12
- **Final completion:** 2022-12
- **Target enrollment:** 280 (ESTIMATED)
- **Last updated:** 2021-02-26


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04772443

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04772443, "Evaluate the Efficacy and Safety of DWJ1506 and DWJ1507". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT04772443. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*